Cargando…
Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746024/ https://www.ncbi.nlm.nih.gov/pubmed/31723830 http://dx.doi.org/10.1097/HS9.0000000000000193 |
| _version_ | 1783451641956007936 |
|---|---|
| author | Decool, Gauthier Domenech, Carine Grardel, Nathalie Plesa, Adriana Raczkiewicz, Imelda Ducourneau, Benoit Ruminy, Philippe Pages, Marie-Pierre Girard, Sandrine Fenwarth, Laurène Preudhomme, Claude Bertrand, Yves Duployez, Nicolas |
| author_facet | Decool, Gauthier Domenech, Carine Grardel, Nathalie Plesa, Adriana Raczkiewicz, Imelda Ducourneau, Benoit Ruminy, Philippe Pages, Marie-Pierre Girard, Sandrine Fenwarth, Laurène Preudhomme, Claude Bertrand, Yves Duployez, Nicolas |
| author_sort | Decool, Gauthier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6746024 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67460242019-11-13 Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion Decool, Gauthier Domenech, Carine Grardel, Nathalie Plesa, Adriana Raczkiewicz, Imelda Ducourneau, Benoit Ruminy, Philippe Pages, Marie-Pierre Girard, Sandrine Fenwarth, Laurène Preudhomme, Claude Bertrand, Yves Duployez, Nicolas Hemasphere Case Report Wolters Kluwer Health 2019-03-05 /pmc/articles/PMC6746024/ /pubmed/31723830 http://dx.doi.org/10.1097/HS9.0000000000000193 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Case Report Decool, Gauthier Domenech, Carine Grardel, Nathalie Plesa, Adriana Raczkiewicz, Imelda Ducourneau, Benoit Ruminy, Philippe Pages, Marie-Pierre Girard, Sandrine Fenwarth, Laurène Preudhomme, Claude Bertrand, Yves Duployez, Nicolas Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title | Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title_full | Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title_fullStr | Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title_full_unstemmed | Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title_short | Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion |
| title_sort | efficacy of tyrosine kinase inhibitor therapy in a chemotherapy-refractory b-cell precursor acute lymphoblastic leukemia with zc3hav1-abl2 fusion |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746024/ https://www.ncbi.nlm.nih.gov/pubmed/31723830 http://dx.doi.org/10.1097/HS9.0000000000000193 |
| work_keys_str_mv | AT decoolgauthier efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT domenechcarine efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT grardelnathalie efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT plesaadriana efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT raczkiewiczimelda efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT ducourneaubenoit efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT ruminyphilippe efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT pagesmariepierre efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT girardsandrine efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT fenwarthlaurene efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT preudhommeclaude efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT bertrandyves efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion AT duployeznicolas efficacyoftyrosinekinaseinhibitortherapyinachemotherapyrefractorybcellprecursoracutelymphoblasticleukemiawithzc3hav1abl2fusion |